歡迎來(lái)到上海谷研實(shí)業(yè)有限公司網(wǎng)站！
咨詢電話：18321818584歡迎來(lái)到上海谷研實(shí)業(yè)有限公司網(wǎng)站！咨詢電話：18321818584
簡(jiǎn)要描述：腫瘤抑制基因LATS1抗體注意事項(xiàng)；This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品型號(hào)：GOY-01K0161廠商性質(zhì)：科研更新時(shí)間：2023-10-24 00:00:00訪 問(wèn) 量：152產(chǎn)品分類
Product Category相關(guān)文章
Related Articles詳細(xì)介紹
商品屬性：
貨號(hào) | 產(chǎn)品名稱 | 規(guī)格 |
GOY-01K0161 | 腫瘤抑制基因LATS1抗體 | 50ul |
GOY-01K0161 | 腫瘤抑制基因LATS1抗體 | 100ul |
GOY-01K0161 | 腫瘤抑制基因LATS1抗體 | 200ul |
英文名稱: LATS1
中文名稱: 腫瘤抑制基因LATS1抗體
別 名；Large tumor suppressor homolog 1; Serine
threonine protein kinase LATS1; WARTS; WARTS protein kinase; LATS1_HUMAN.
研究領(lǐng)域；腫瘤 免疫學(xué) 轉(zhuǎn)錄調(diào)節(jié)因子
抗體來(lái)源；Rabbit
克隆類型；Polyclonal
交叉反應(yīng)；(predicted: Human, Mouse, Rat,
Chicken, Pig, Cow, Horse, Rabbit, )
產(chǎn)品應(yīng)用；WB=1:500-2000
ELISA=1:5000-10000 IHC-P=1:100-500 （石蠟切片需做抗原修復(fù)）
not yet tested in
other applications.
optimal
dilutions/concentrations should be determined by the end user.
理論分子量；124kDa
細(xì)胞定位；細(xì)胞漿
性 狀；Liquid
濃 度；1mg/ml
免 疫 原；KLH conjugated synthetic
peptide derived from human LATS1: 821-950/1130
亞 型；IgG
純化方法；affinity purified by Protein A
保存條件；Shipped at 4℃. Store at -20 °C for one year. Avoid
repeated freeze/thaw cycles.
注意事項(xiàng)；This product as supplied is
intended for research use only, not for use in human, therapeutic or diagnostic
applications.
產(chǎn)品介紹 The protein encoded by this
gene is a putative serine/threonine kinase that localizes to the mitotic
apparatus and complexes with cell cycle controller CDC2 kinase in early
mitosis. The protein is phosphorylated in a cell-cycle dependent manner, with
late prophase phosphorylation remaining through metaphase. The N-terminal
region of the protein binds CDC2 to form a complex showing reduced H1 histone
kinase activity, indicating a role as a negative regulator of CDC2/cyclin A. In
addition, the C-terminal kinase domain binds to its own N-terminal region,
suggesting potential negative regulation through interference with complex
formation via intramolecular binding. Biochemical and genetic data suggest a
role as a tumor suppressor. This is supported by studies in knockout mice
showing development of soft-tissue sarcomas, ovarian stromal cell tumors and a
high sensitivity to carcinogenic treatments. [provided by RefSeq].
Function:
Negative regulator of YAP1 in the Hippo signaling pathway that plays a pivotal role in organ size control and tumor suppression by restricting proliferation and promoting apoptosis. The core of this pathway is composed of a kinase cascade wherein STK3/MST2 and STK4/MST1, in complex with its regulatory protein SAV1, phosphorylates and activates LATS1/2 in complex with its regulatory protein MOB1, which in turn phosphorylates and inactivates YAP1 oncoprotein and WWTR1/TAZ. Phosphorylation of YAP1 by LATS1 inhibits its translocation into the nucleus to regulate cellular genes important for cell proliferation, cell death, and cell migration. Acts as a tumor suppressor which plays a critical role in maintenance of ploidy through its actions in both mitotic progression and the G1 tetraploidy checkpoint. Negatively regulates G2/M transition by down-regulating CDK1 kinase activity. Involved in the control of p53 expression. Affects cytokinesis by regulating actin polymerization through negative modulation of LIMK1. May also play a role in endocrine function.
實(shí)驗(yàn)流程：
（1）特異性結(jié)合抗原：抗體本身不能直接溶解或殺傷帶有特異抗原的靶細(xì)胞，通常需要補(bǔ)體或吞噬細(xì)胞等共同發(fā)揮效應(yīng)以清除病原微生物或?qū)е虏±頁(yè)p傷。然而，抗體可通過(guò)與病毒或毒素的特異性結(jié)合，直接發(fā)揮中和病毒的作用。
（2）活補(bǔ)體：IgM、IgG1、IgG2和IgG3可通過(guò)經(jīng)典途徑激活補(bǔ)體，凝聚的IgA、IgG4和IgE可通過(guò)替代途徑激活補(bǔ)體。
（3）結(jié)合細(xì)胞：不同類別的免疫球蛋白，可結(jié)合不同種的細(xì)胞，參與免疫應(yīng)答。
（4）可通過(guò)胎盤及粘膜：免疫球蛋白G（IgG）能通過(guò)胎盤進(jìn)入胎兒血流中，使胎兒形成自然被動(dòng)
免疫。免疫球蛋白A（IgA）可通過(guò)消化道及呼吸道粘膜，是粘膜局部抗感染免疫的主要因素。
（5）具有抗原性：抗體分子是一種蛋白質(zhì)，也具有刺機(jī)體產(chǎn)生免疫應(yīng)答的性能。不同的免疫球蛋白分子，各具有不同的抗原性。
（6）抗體對(duì)理化因子的抵抗力與一般球蛋白相同：不耐熱，60～70℃即被破壞。各種酶及能使蛋白質(zhì)凝固變性的物質(zhì)，均能破壞抗體的作用?？贵w可被中性鹽類沉淀。在生產(chǎn)上?？捎昧蛩徜@或硫酸鈉從免疫血清中沉淀出含有抗體的球蛋白，再經(jīng)透析法將其純化。
抗體的制備過(guò)程：
1.免疫原：普通的大分子蛋白，通過(guò)分子克隆構(gòu)建載體并在大腸桿菌中進(jìn)行誘導(dǎo)表達(dá)獲得重組蛋白，純化鑒定后可直接作為免疫原；小分子蛋白或化合物等分子量小，需要偶聯(lián)載體對(duì)該分子進(jìn)行改造才能使其成為具有免疫原性的抗原，常見(jiàn)偶聯(lián)載體如BSA、OVA、HAS等。
2. 免疫動(dòng)物：常用于制備抗血清的動(dòng)物有豚鼠、家兔、雞、大小鼠等，大量生產(chǎn)時(shí)需要用到狗、綿羊、山羊等。
3.免疫血清的收集：一般家兔、綿羊、山羊可采用靜動(dòng)脈采血，家兔、豚鼠、大鼠、雞可采用心臟采血，家兔、山羊、綿羊可采用靜脈采血。
4. 腫瘤抑制基因LATS1抗體免疫血清的純化與鑒定：得到的抗血清需要進(jìn)一步的純化，利用偶聯(lián)了抗原的親和柱進(jìn)行層析，具有高效，特異性強(qiáng)，純度高的特定。接著要鑒定純化蛋白的含量、相對(duì)分子的質(zhì)量、純度以及特異性。
5.免疫血清的保存：抗體一般比較穩(wěn)定，在-80℃ ～-20 ℃可以保存約5年而不會(huì)影響效價(jià)，而真空干燥保存時(shí)間可以更久。保存前需經(jīng)除菌并添加防腐劑。
產(chǎn)品咨詢
聯(lián)系人：銷售部
地址：上海市嘉定區(qū)澄瀏公路52號(hào)盛創(chuàng)企業(yè)
郵箱：[email protected]
手機(jī)：18321818584 / 15026555973歡迎您關(guān)注我們的微信了解更多信息
掃一掃電話
微信掃一掃